LYZ and infection: It has been shown earlier that graRS single mutants are resistant to the muramidase activity of lysozyme but are sensitive to cationic antimicrobial peptides, including the human lysozyme-derived peptide 107R-A-W-V-A-W-R-N-R115 (LP9), polymyxin B, or gallidermin, indicating the potential of AMPs for treating infections [142].